After claiming its approval in Europe earlier this year, Abbott has secured the FDA’s go-ahead for its Volt pulsed field ablation system for irregular heart rhythms, a step forward in an | With the U.

I felt fine, but my Whoop data told a different story. Paying attention led to early detection and a successful treatment.

The latest update is out from Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:IMR) ). Imricor Medical Systems has ...

Background The growing population of patients with adult congenital heart disease (ACHD) present complex lifelong care needs ...

The King Abdullah University Hospital (KAUH) has performed its first catheter-based cardiac ablation procedures for the treatment of cardiac arrhythmias, using advanced electrophysiology and cardiac ...

Abbott will soon enter the competitive U.S. pulsed field ablation (PFA) market, having just received FDA approval for its ...

Abbott (NYSE: ABT) announced today that the FDA approved its Volt pulsed field ablation (PFA) system to treat patients with ...

The FDA approved Abbott's Volt PFA System for atrial fibrillation, supported by VOLT-AF trial data showing strong safety and ...

Abbott can now compete with Medtronic, Boston Scientific and J&J in the U.S. for the fast-growing pulsed field ablation ...

Non-small cell lung cancer (NSCLC) remains the most prevalent type of lung cancer and a leading cause of cancer-related mortality worldwide. Surgical ...

When CMS quietly updated the Medically Unlikely Edit (MUE) for CPT 64772 from two to six units for 2026, it didn’t make headlines, but it should have. This change isn’t simply a coding adjustment. It ...